Business Context and Reporting Period
This Form 8-K Current Report was filed by RXi Pharmaceuticals Corporation (noting the metadata reference to SELLAS Life Sciences Group, Inc. appears to be a discrepancy as the filing text identifies RXi Pharmaceuticals) on February 28, 2011. The report details the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of Units consisting of Common Stock and Warrants.
- Securities Issued: 6,000,000 shares of Common Stock, 3,000,000 Thirteen-Month Warrants, and 3,000,000 Five-Year Warrants.
- Offering Price: $1.35 per Unit.
- Underwriting Discount: 7.0% (Units purchased by underwriters at $1.2555).
- Expected Net Proceeds: Approximately $7,358,000 (assuming no warrant exercise and deducting underwriting discounts and estimated expenses).
- Warrant Terms:
- Thirteen-Month Warrants: Exercise price of $1.70 per share.
- Five-Year Warrants: Exercise price of $1.87 per share.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement dated March 1, 2011, with Lazard Capital Markets LLC as the sole book-running manager and ROTH Capital Partners, LLC as co-manager. The offering is expected to close on March 4, 2011, subject to customary closing conditions. The Warrants include full-ratchet anti-dilution protection.
Guidance, Outlook, and Restrictions
The filing does not provide specific financial guidance or operational outlook beyond the capital raise. However, it notes a significant restriction: the Company agreed to a 90-day lock-up period following the Offering, during which it cannot offer or sell additional Common Stock or convertible securities without the Underwriters' written consent. Exceptions are made for employee benefit plans and strategic alliances.
Investor Verification Checklist
- Verify the closing date of the Offering (expected March 4, 2011) and actual net proceeds received.
- Confirm the final share count post-offering to assess immediate dilution impact.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification obligations.
- Monitor the exercise of the Thirteen-Month and Five-Year Warrants to understand potential future dilution.
- Clarify the discrepancy between the metadata company name (SELLAS Life Sciences Group, Inc.) and the registrant name in the filing (RXi Pharmaceuticals Corporation).